Table 1.
Fusion transcripts detected in the blood samples of prostate cancer patients.
| Fusion | MAN2A1-FER | TRMT11-GRIK2 | mTOR-TP53BP1 | CCNH-c5orf30 | KDM4B-AC011523.2 | SLC45A2-AMACR | TMEM135-CCDC67 | LRRC59-FLJ60017 | Pten-NOLC1 | Any fusion |
|---|---|---|---|---|---|---|---|---|---|---|
| 82.3% (121/147) | 0% (0/147) | 4% (6/147) | 5.4% (8/147) | 1.4% (2/147) | 41.5% (61/147) | 0% (0/147) | 0% (0/147) | 38.8% (57/147) | 89.8% (132/147) | |
| Pre-operation PSA | 7.36 | N/A | 3.83 | 9.64 | 8.43 | 7.67 | N/A | N/A | 7.60 | 7.89 |
| Gleason 6 | 81.3% (13/16) | 0% (0/16) | 6.3% (1/16) | 0% (0/16) | 6.3% (1/16) | 37.5% (6/16) | 0% (0/16) | 0% (0/16) | 62.5% (10/16) | 87.5% (14/16) |
| Gleason 7 | 81% (81/100) | 0% (0/100) | 5% (5/100) | 5% (5/100) | 1% (1/100) | 42% (42/100) | 0% (0/100) | 0% (0/100) | 38% (38/100) | 90% (90/100) |
| Gleason 8 | 91.7% (11/12) | 0% (0/12) | 0% (0/12) | 8.3% (1/12) | 0% (0/12) | 50% (6/12) | 0% (0/12) | 0% (0/12) | 41.7% (5/12) | 91.7% (11/12) |
| Gleason 9 | 83.3% (15/18) | 0% (0/18) | 0% (0/18) | 11.1% (2/18) | 0% (0/18) | 33.3% (6/18) | 0% (0/18) | 0% (0/18) | 16.7% (3/18) | 88.9% (16/18) |
| Gleason 10 | 100% (1/1) | 0% (0/1) | 0% (0/1) | 0% (0/1) | 0% (0/1) | 100% (1/1) | 0% (0/1) | 0% (0/1) | 100% (1/1) | 100% (1/1) |
| T2a | 78.6% (11/14) | 0% (0/14) | 0% (0/14) | 7.1% (1/14) | 0% (0/14) | 35.7% (5/14) | 0% (0/14) | 0% (0/14) | 42.9% (6/14) | 92.9% (13/14) |
| T2c | 77.3% (51/66) | 0% (0/66) | 6.1% (4/66) | 4.5% (3/66) | 1.5% (1/66) | 45.5% (30/66) | 0% (0/66) | 0% (0/66) | 40.9% (27/66) | 87.9% (58/66) |
| T3a | 92.3% (48/52) | 0% (0/52) | 3.8% (2/52) | 5.8% (3/52) | 1.9% (1/52) | 42.3% (22/52) | 0% (0/52) | 0% (0/52) | 40.4% (21/52) | 94.2% (49/52) |
| T3c | 73.3% (11/15) | 0% (0/15) | 0% (0/15) | 6.7% (1/15) | 0% (0/15) | 26.7% (4/15) | 0% (0/15) | 0% (0/15) | 20% (3/15) | 80% (12/15) |
| N0 | 82.4% (108/131) | 0% (0/131) | 4.6% (6/131) | 4.6% (6/131) | 1.5% (2/131) | 42.7% (56/131) | 0% (0/131) | 0% (0/131) | 41.22 (54/131) | 90.8% (118/131) |
| N1 | 81.3% (13/16) | 0% (0/16) | 0% (0/16) | 12.5% (2/16) | 0% (0/16) | 31.25% (5/16) | 0% (0/16) | 0% (0/16) | 18.8% (3/16) | 87.5% (14/16) |
| 5 year NOMOGRAM | ||||||||||
| 95–99 | 25% (3/12) | 0% (0/12) | 8.3% (1/12) | 8.3% (1/12) | 0% (0/12) | 41.7% (5/12) | 0% (0/12) | 0% (0/12) | 33.3% (4/12) | 58.3% (7/12) |
| 90–94 | 50% (2/4) | 0% (0/4) | 0% (0/4) | 0% (0/4) | 0% (0/4) | 50% (2/4) | 0% (0/4) | 0% (0/4) | 50% (2/4) | 100% (4/4) |
| 80–89 | 88.9% (8/9) | 0% (0/9) | 11.1% (1/9) | 22.2% (2/9) | 11.1% (1/9) | 44.4% (4/9) | 0% (0/9) | 0% (0/9) | 33.3% (3/9) | 88.9% (8/9) |
| 60–79 | 72.7% (8/11) | 0% (0/11) | 0% (0/11) | 18.2% (2/11) | 0% (0/11) | 45.5% (5/11) | 0% (0/11) | 0% (0/11) | 18.2% (2/11) | 81.8% (9/11) |
| 10 year NOMOGRAM | ||||||||||
| 90–99 | 25% (3/12) | 0% (0/12) | 8.3% (1/12) | 8.3% (1/12) | 0% (0/12) | 41.7% (5/12) | 0% (0/12) | 0% (0/12) | 33.3% (4/12) | 58.3% (7/12) |
| 80–89 | 60% (3/5) | 0% (0/5) | 0% (0/5) | 20% (1/5) | 0% (0/5) | 40% (2/5) | 0% (0/5) | 0% (0/5) | 40% (2/5) | 100% (5/5) |
| 60–79 | 81.8% (9/11) | 0% (0/11) | 9.1% (1/11) | 9.1% (1/11) | 9.1% (1/11) | 45.5% (5/11) | 0% (0/11) | 0% (0/11) | 27.3% (3/11) | 90.9% (10/11) |
| 40–59 | 75% (6/8) | 0% (0/8) | 0% (0/8) | 25% (2/8) | 0% (0/8) | 50% (4/8) | 0% (0/8) | 0% (0/8) | 25% (2/8) | 75% (6/8) |
| Healthy individuals | 0% (0/14) | 0% (0/14) | 0% (0/14) | 0% (0/14) | 0% (0/14) | 0% (0/14) | 0% (0/14) | 0% (0/14) | 0% (0/14) | 0% (0/14) |